PRAME and CTCFL-reactive TCRs for the treatment of ovarian cancer

Recurrent disease emerges in the majority of patients with ovarian cancer (OVCA). Adoptive T-cell therapies with T-cell receptors (TCRs) targeting tumor-associated antigens (TAAs) are considered promising solutions for less-immunogenic ‘cold’ ovarian tumors. In order to treat a broader patient popul...

Descripción completa

Detalles Bibliográficos
Autores principales: van Amerongen, Rosa A., Tuit, Sander, Wouters, Anne K., van de Meent, Marian, Siekman, Sterre L., Meeuwsen, Miranda H., Wachsmann, Tassilo L. A., Remst, Dennis F. G., Hagedoorn, Renate S., van der Steen, Dirk M., de Ru, Arnoud H., Verdegaal, Els M. E., van Veelen, Peter A., Falkenburg, J. H. Frederik, Heemskerk, Mirjam H. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10070997/
https://www.ncbi.nlm.nih.gov/pubmed/37026005
http://dx.doi.org/10.3389/fimmu.2023.1121973

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10070997/
https://www.ncbi.nlm.nih.gov/pubmed/37026005
http://dx.doi.org/10.3389/fimmu.2023.1121973

Ejemplares similares